Researchers conduct research new treatment of cancer stem cells

Many cancer patients enter the remission after chemotherapy, but they will continue to relapse after the treatment. More and more evidence suggests that this is due to the infinite reproduction of cancer stem cells may grow new tumors. A team from Milan, Italy, designed a program specifically targeted to cancer stem cells in certain cancers and reduced their tumorigenic potential. The study was published in the EMBO Molecular Medicine, which has published many studies on various recombinant proteins like recombinant rat proteins.

Each of our bodies has stem cells that are constantly splitting and renewing cells in the body. The team led by Pier Paolo Di Fiore and Salvatore Pece explored the role of Numb protein in maintaining stem cells in normal mammary gland development and found that Numb protein is necessary to maintain balance before stem cell and gland differentiation. Numb upregulates p53, a protein that blocks cell division. When Numb is deleted, p53 is also reduced, leading to increased self-replication of stem cells, which may lead to tumor formation.

In many breast cancers, Numb concentrations are lower, which is associated with poor prognosis. In this study, the role of Numb in these tumors was observed and found to be deficient in Numb's tumors, and the number of cancer stem cells increased, thus providing higher proliferation and growth potential for tumors. In addition, the researchers found that p53 plays an important role in it. When the concentration of Numb decreases, the concentration of p53 will also decrease. However, when p53 levels are recovered by blocking the degradation of Nutlin-3, the tumor is less aggressive and has fewer cancer stem cells. Many drugs targeting p53 pathways, such as Nutlin-3, are currently in clinical development.

Finally, the researchers examined the potential for the combination of Nutlin-3 and paclitaxel (a common chemotherapeutic agent). Although paclitaxel alone can reduce the tumor, the risk of recurrence is great once terminating the treatment. The combination of paclitaxel and Nutlin-3 not only enhances the response of paclitaxel to tumors, but also prevents Numb-deficient tumors from proliferating after treatment has ceased. This indicates that Nutlin-3 or similar drugs have the potential to fight against chemical resistance caused by cancer stem cells.

In the context of current research, researchers have developed preclinical model systems that specifically capture the effects on cancer stem cell therapy. All results were based on transplanting the patient's tumor cells into mice and then studying the presence of stem cells or the invasive nature of the cancer by a variety of methods. The system of testing different effects of different compounds on cancer stem cells may be a valuable tool in future experiments.

These preclinical findings suggest that patients with breast cancer with a defective expression of Numb may be eligible for the use of the currently clinically developed Nutlin-3 similar drugs. Using the same preclinical model, researchers are testing the efficacy of this candidate drug for cancer stem cells, as well as the possibility of minimal toxicity of standard chemotherapy regimens in the treatment of human breast cancer. By the way, Flarebio provides you with high-quality recombinant proteins such as recombinant ITGB2 at good prices.